Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
株式のランク #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
株価
$0.94180721
時価総額
$22.26M
変化(1日)
0.38%
変化(1年)
-14.35%
FR
取引 Valbiotis SA (ALVAL)

カテゴリー

Valbiotis SA(ALVAL)のEPS
December 2025 時点のEPS TTM: $-0.57
Valbiotis SAの最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-0.57です。2023年末には、EPSは$-0.65で、2022年のEPS$-1.31と減少でした。
Valbiotis SAのEPS履歴(2015から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-0.57 -12.89%
2024 $-0.66 0.52%
2023 $-0.65 -50.16%
2022 $-1.31 21.14%
2021 $-1.08 73.93%
2020 $-0.62 -52.69%
2019 $-1.31 -13.46%
2018 $-1.52 37.41%
2017 $-1.10 517.05%
2016 $-0.18 -99.73%
2015 $-65.94 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$4.36 -858.10%
DK
$17.01 -3,058.78%
US
$42.53 -7,497.81%
US
$9.62 -1,773.47%
BE
$23.88 -4,253.77%
NL